ASLAN PHARMACEUTICALS LT ADR (ASLN)
Institutional ownership reported to the SEC as of Q2 2026, across 31 quarters.
1
Reporting holders
$17
Reported value
0.0%
Held as options
+0
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | $17 | 29 | 0.00% | 8q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | $17 | 29 | 0 | 0 | 0 | 0.0% |
| Q1 2026 | 1 | $17 | 29 | 0 | 0 | 0 | 0.0% |
| Q4 2025 | 1 | $17 | 29 | 0 | 0 | 0 | 0.0% |
| Q3 2025 | 1 | $17 | 29 | 0 | 0 | 1 | 0.0% |
| Q2 2025 | 1 | $60 | 101 | 0 | 0 | 1 | 0.0% |
| Q1 2025 | 1 | $95 | 160 | 0 | 0 | 0 | 0.0% |
| Q4 2024 | 1 | $95 | 160 | 0 | 0 | 0 | 0.0% |
| Q3 2024 | 1 | $95 | 160 | 1 | 0 | 0 | 0.0% |
| Q2 2024 | 18 | $895.5K | 2,971,747 | 2 | 6 | 2 | 0.4% |
| Q1 2024 | 18 | $1.8M | 2,895,663 | 5 | 1 | 6 | 0.8% |
| Q4 2023 | 18 | $1.7M | 3,330,548 | 6 | 2 | 4 | 0.2% |
| Q3 2023 | 15 | $10.4M | 5,589,600 | 2 | 2 | 4 | 0.1% |
| Q2 2023 | 17 | $24.4M | 6,708,089 | 5 | 1 | 4 | 0.0% |
| Q1 2023 | 12 | $9.4M | 5,523,721 | 11 | 0 | 0 | 0.0% |
| Q4 2022 | 17 | $4.8M | 13,490,243 | 2 | 3 | 5 | 0.0% |
| Q3 2022 | 27 | $12.8M | 22,033,101 | 5 | 3 | 10 | 0.0% |
| Q2 2022 | 25 | $11.3M | 23,410,500 | 0 | 6 | 6 | 0.1% |
| Q1 2022 | 31 | $23.3M | 25,448,049 | 4 | 7 | 11 | 0.1% |
| Q4 2021 | 32 | $30.0M | 27,485,391 | 7 | 6 | 8 | 0.1% |
| Q3 2021 | 37 | $43.2M | 25,192,227 | 14 | 10 | 7 | 1.5% |
| Q2 2021 | 30 | $87.9M | 26,642,951 | 1 | 13 | 6 | 0.0% |
| Q1 2021 | 40 | $88.4M | 26,401,083 | 29 | 5 | 4 | 0.0% |
| Q4 2020 | 12 | $8.2M | 6,290,609 | 7 | 5 | 0 | 0.0% |
| Q3 2020 | 7 | $6.5M | 3,408,553 | 1 | 1 | 2 | 0.0% |
| Q2 2020 | 9 | $7.0M | 3,488,801 | 1 | 2 | 2 | 0.0% |
| Q1 2020 | 10 | $3.4M | 3,364,694 | 1 | 4 | 3 | 0.0% |
| Q4 2019 | 14 | $6.7M | 3,294,140 | 11 | 0 | 1 | 0.0% |
| Q3 2019 | 6 | $3.9M | 2,281,944 | 1 | 2 | 1 | 0.0% |
| Q2 2019 | 7 | $7.0M | 2,293,688 | 1 | 1 | 4 | 0.0% |
| Q1 2019 | 8 | $10.7M | 2,509,668 | 1 | 2 | 4 | 0.0% |
| Q4 2018 | 8 | $11.0M | 2,997,835 | 0 | 0 | 0 | 0.0% |